


PRODUCT INFORMATION



CP 80,633

Item No. 13183

CAS Registry No.: 135637-46-6
Formal Name: 5-[3-[(1S,2S,4R)-bicyclo[2.2.1]hept-2-yloxy]-methoxyphenyl]tetrahydro-2-(1H)-pyrimidinone
MF: C₁₈H₂₄N₂O₃
FW: 316.4
Purity: ≥95%
UV/Vis.: 230, 281 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CP 80,633 is supplied as a crystalline solid. A stock solution may be made by dissolving the CP 80,633 in the solvent of choice, which should be purged with an inert gas. CP 80,633 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of CP 80,633 in DMSO is approximately 2 mg/ml and approximately 3 mg/ml in DMF.

CP 80,633 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CP 80,633 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. CP 80,633 has a solubility of approximately 0.1 mg/ml in a 1:10 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Phosphodiesterases (PDE) enzymatically convert the cyclic nucleotide second messengers cAMP and cGMP to 5'-AMP and 5'-GMP, respectively, thus terminating signal transduction. The cAMP-specific PDE4 isoforms may be particularly important in certain respiratory and neurological diseases.^{1,2} CP 80,633 is a selective inhibitor of PDE4 (IC₅₀ = 1.27 μM for PDE4 versus >100 μM for PDE1, PDE2, PDE3, and PDE5).³ It potentiates PGE₁-dependent increases in cAMP levels in eosinophils, monocytes, and T-cells, inhibits eosinophil superoxide production (IC₅₀ < 0.6 μM), and blocks LPS-induced TNF-α release from monocytes (IC₅₀ = 0.22 μM).³ CP 80,633 (1 mg/kg) significantly reduces antigen-induced airway inflammation in atopic guinea pigs, monkeys, and mice.^{4,5}

References

1. Spina, D. Br. J. Pharmacol. **155**, 308-315 (2008).
2. O'Donnell, J.M. and Zhang, H.-T. Trends Pharmacol. Sci. **25**(3), 158-163 (2004).
3. Cohan, V.L., Showell, H.J., Fisher, D.A., et al. J. Pharmacol. Exp. Ther. **278**(3), 1356-1361 (1996).
4. Turner, C.R., Cohan, V.L., Cheng, J.B., et al. J. Pharmacol. Exp. Ther. **278**(3), 1349-1355 (1996).
5. Cheng, J.B., Watson, J.W., Pazoles, C.J., et al. J. Pharmacol. Exp. Ther. **280**, 621-626 (1997).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/07/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM